Shattuck Labs, INC 8-K filings

Shattuck Labs announced strong Q2 2026 financial results, highlighting positive Phase 1 data for SL-325 and a cash runway extending into 2029.

Shattuck Labs, Inc. announced the pricing of its underwritten public offering of common stock and pre-funded warrants, raising capital through the sale of over 18 million shares and warrants.

Shattuck Labs reports promising Phase 1 trial results for its SL-325 DR3 blocking antibody, with plans for a Phase 2b trial in Crohn's disease and advancement of its SL-846 bispecific candidate.

Shattuck Labs, Inc. announced the outcomes of its 2026 Annual Meeting of Stockholders, including the election of directors and approval of amendments to its 2020 Equity Incentive Plan.

Shattuck Labs announced Q1 2026 financial results, highlighting the completion of Phase 1 enrollment for SL-325 and providing an updated cash runway into 2029.

Shattuck Labs announced its full-year 2025 financial results, reporting reduced net losses and significant progress in its lead clinical program, SL-325.

Shattuck Labs, Inc. announced the date for its 2026 annual meeting of stockholders and revised deadlines for proposal submissions.

Shattuck Labs, Inc. has entered into a sales agreement with Leerink Partners LLC to offer and sell up to $75 million of its common stock through an at-the-market offering.

Shattuck Labs announced third quarter 2025 financial results, highlighted by the dosing of first participants in its SL-325 Phase 1 trial and a private placement securing funding into 2029.

Shattuck Labs announced its third quarter 2025 financial results, highlighted by the dosing of first participants in the Phase 1 clinical trial for SL-325 and a successful $103 million private placement.

Shattuck Labs, Inc. announced the closing of a private placement of up to $103 million and significant changes to its Board of Directors, including new appointments and resignations.

Shattuck Labs reported reduced Q2 2025 net loss and secured up to $103 million in a private placement, extending its cash runway into 2029 while advancing its lead drug candidate, SL-325, into Phase 1 clinical trials.

Shattuck Labs, Inc. announced an oversubscribed private placement expected to raise up to $103 million, primarily to fund its SL-325 clinical development program through multiple Phase 2 trials and extend its cash runway into 2029.

Shattuck Labs, Inc. announced that its stockholders elected all director nominees and ratified KPMG LLP as its independent auditor during the 2025 Annual Meeting held on July 10, 2025.

Shattuck Labs announces its Q1 2025 financial results, highlighting progress with its SL-325 program and a cash balance expected to fund operations into 2027.

Shattuck Labs announces its Q4 and full-year 2024 financial results, highlighting the advancement of SL-325, a potential first-in-class DR3 blocking antibody, and a cash runway into 2027.

Shattuck Labs reported its Q3 2024 financial results, highlighted by a strategic focus on SL-325 development and a cash runway extending into 2027.

Shattuck Labs is discontinuing its SL-172154 program and restructuring its operations, including a 40% workforce reduction, to prioritize the development of its SL-325 DR3 antagonist program.

Shattuck Labs reported encouraging interim data from its SL-172154 clinical trials, along with its second quarter 2024 financial results.

Shattuck Labs reports encouraging interim results from its Phase 1B trial of SL-172154 in combination with azacitidine for higher-risk myelodysplastic syndromes and TP53 mutant acute myeloid leukemia, leading to a focus on these indications.

Shattuck Labs has amended its previous 8-K filing to announce the appointment of two new directors to key board committees, effective June 11, 2024.

Shattuck Labs successfully held its 2024 Annual Meeting, electing all director nominees and ratifying KPMG LLP as its independent auditor.

Shattuck Labs announced its first quarter 2024 financial results, highlighted by clinical trial advancements and a strategic collaboration with Ono Pharmaceutical.

Shattuck Labs has appointed Dr. Kate Sasser and Dr. Clay Siegall to its Board of Directors, effective March 1, 2024, bringing significant industry experience to the company.

Shattuck Labs reported positive clinical trial data for its lead drug candidate, SL-172154, and secured $50 million in funding, extending its cash runway into 2026.

Shattuck Labs has partnered with Ono Pharmaceutical to research and develop bifunctional fusion proteins, potentially earning up to $226.5 million plus royalties.